Wonsart 40H Tablet contains a combination of Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg, formulated for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduction in blood pressure. Hydrochlorothiazide is a thiazide diuretic that acts on the distal convoluted tubules in the kidneys to promote sodium and water excretion, reducing plasma volume and peripheral resistance. The synergistic effect of these two agents provides effective and sustained blood pressure control, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Wonsart 40H is indicated for patients who require combination therapy after monotherapy has proven insufficient or for those who benefit from dual mechanism treatment. It is important to monitor renal function, electrolyte levels, and blood pressure regularly during therapy. Caution is advised in patients with impaired renal or hepatic function, electrolyte imbalances, or hypersensitivity to sulfonamides. Wonsart 40H should be used under medical supervision, with dosage adjustments based on clinical response and tolerability.